首页 > 市场调查报告书 > 製药

个人化医学

市场调查报告书

商品编码

1746515

日本伴随诊断市场报告（按产品与服务、技术（免疫组织化学、聚合酶炼式反应、原位杂交、即时 PCR、基因定序等）、适应症、最终用户和地区）2025 年至 2033 年

Japan Companion Diagnostics Market Report by Product & Service, Technology (Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing, and Others), Indication, End User, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 122 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2024年，日本伴随诊断市场规模达4.495亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到12.085亿美元，2025-2033年期间的复合年增长率（CAGR）为11.60%。癌症发生率的上升、个人化医疗需求的日益增长以及新一代定序（NGS）等技术的持续进步，是推动市场成长的主要因素。

伴随诊断是指帮助医师确定最适合治疗策略的医学检测。它们旨在检测患者组织或血液样本中存在的特定生物标记物，从而判断患者是否可能对特定药物或治疗方法产生积极反应。此外，它们还能深入研究患者复杂的生物学特征和作用机制 (MOA)，帮助医护人员了解潜在的药物副作用。伴随诊断在个人化医疗中得到了广泛的应用，它考虑到每位患者的独特特征，例如其基因组成，以确定最佳治疗方案。此外，伴随诊断在检测癌症患者的特定基因突变或识别丙型肝炎患者的生物标记方面的应用也日益增多。

日本伴随诊断市场趋势：

日本伴随诊断市场正在经历显着增长，主要原因是各种癌症类型发病率的上升，这推动了对更精准、更有针对性的癌症治疗的需求。此外，对根据每位患者独特特征量身定制的个人化医疗的需求不断增长，进一步增强了市场前景的乐观。同时，针对各种感染、心血管、神经系统和发炎疾病的标靶药物和疗法的广泛应用，也是另一个重要的成长动力。日本伴随诊断的监管环境良好，越来越多的检测获得批准。再加上全球临床试验数量的增加，共同推动了市场的成长。诊断技术的持续进步，例如新一代定序 (NGS) 和液体活检的出现，对于识别先前难以检测的生物标记至关重要。创新基因组学技术的发展发挥关键作用，有助于识别对指导治疗决策至关重要的基因突变和生物标誌物，从而推动市场成长。此外，生物标记在药物开发中的应用日益增多、对精准医疗的大量投资以及消费者对伴随诊断益处的认识不断提高等因素预计将在预测期内为区域市场带来丰厚的成长机会。

日本伴随诊断市场细分：

产品与服务洞察：

检测试剂盒和试剂
软体和服务

技术洞察：

免疫组织化学（IHC）
聚合酶炼式反应（PCR）
原位杂交（ISH）
实时PCR（RT-PCR）
基因定序
其他的

指示见解：

癌症
- 肺癌
- 乳癌
- 大肠直肠癌
- 胃癌
- 黑色素瘤
- 其他的
神经系统疾病
传染病
心血管疾病
其他的

最终用户洞察：

製药和生物製药公司
参考实验室
合约研究组织
其他的

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪錶板和公司评估象限等竞争分析。此外，报告还提供了所有主要公司的详细资料。

本报告回答的关键问题：

日本伴随诊断市场迄今表现如何？未来几年将如何表现？
COVID-19 对日本伴随诊断市场有何影响？
日本伴随诊断市场根据产品和服务的分布是怎样的？
日本伴随诊断市场依技术如何划分？
日本伴随诊断市场根据适应症的划分是怎样的？
根据最终用户，日本伴随诊断市场是如何分類的？
日本伴随诊断市场的价值链分为哪些阶段？
日本伴随诊断的主要驱动因素和挑战是什么？
日本伴随诊断市场的结构是怎么样的？主要参与者是谁？
日本伴随诊断市场的竞争程度如何？

本报告回答的关键问题：

日本伴随诊断市场迄今表现如何？未来几年将如何表现？
COVID-19 对日本伴随诊断市场有何影响？
日本伴随诊断市场根据产品和服务的分布是怎样的？
日本伴随诊断市场依技术如何划分？
日本伴随诊断市场根据适应症的划分是怎样的？
根据最终用户，日本伴随诊断市场是如何分類的？
日本伴随诊断市场的价值链分为哪些阶段？
日本伴随诊断的主要驱动因素和挑战是什么？
日本伴随诊断市场的结构是怎么样的？主要参与者是谁？
日本伴随诊断市场的竞争程度如何？

Japan companion diagnostics market size reached USD 449.5 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,208.5 Million by 2033, exhibiting a growth rate (CAGR) of 11.60% during 2025-2033. The rising incidence of cancer, the growing need for personalized medicine, and continuous technological advancements like next-generation sequencing (NGS), are among the primary factors propelling the market growth.

Companion diagnostics refer to medical tests that aid physicians in identifying the most suitable treatment strategy. They are crafted to detect specific biomarkers present in a patient's tissue or blood sample, indicating whether the patient is likely to respond positively to a particular drug or therapeutic approach. Additionally, they delve into the intricate biological profile and mechanism of action (MOA) of patients, assisting healthcare professionals in comprehending potential medication side effects. The widespread application of companion diagnostics is evident in personalized medicine, where it takes into account the distinct characteristics of each patient, such as their genetic composition, to determine the optimal treatment course. Beyond this, there is a growing use of companion diagnostics for examining specific genetic mutations in cancer patients or identifying biomarkers in those with hepatitis C.

Japan Companion Diagnostics Market Trends:

The Japan companion diagnostics market is experiencing significant growth, primarily propelled by the increasing incidence of diverse cancer types, which is fostering the demand for more precise and targeted cancer treatments. Additionally, the escalating demand for personalized medicines, tailored to the unique characteristics of each patient, further contributes to the optimistic market outlook. Simultaneously, the widespread adoption of targeted drugs and therapies addressing various infectious, cardiovascular, neurological, and inflammatory conditions serves as another substantial growth driver. The regulatory landscape for companion diagnostics in Japan is favorable, with an increasing number of tests receiving approvals. This, coupled with the expanding number of global clinical trials, strengthens the market growth. Ongoing advancements in diagnostic technologies, such as the emergence of next-generation sequencing (NGS) and liquid biopsy, are pivotal, enabling the identification of previously challenging-to-detect biomarkers. The development of innovative genomic technologies plays a key role, facilitating the identification of genetic mutations and biomarkers crucial for guiding treatment decisions, thereby fueling market growth. Additionally, factors like the growing use of biomarkers in drug development, substantial investments in precision medicine, and heightened consumer awareness regarding the benefits of companion diagnostics are projected to present lucrative growth opportunities for the regional market over the forecasted period.

Japan Companion Diagnostics Market Segmentation:

Product & Service Insights:

Assays, Kits and Reagents
Software and Services

Technology Insights:

Immunohistochemistry (IHC)
Polymerase Chain Reaction (PCR)
In-situ Hybridization (ISH)
Real-time PCR (RT-PCR)
Gene Sequencing
Others

Indication Insights:

Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Gastric Cancer
- Melanoma
- Others
Neurological Diseases
Infectious Diseases
Cardiovascular Diseases
Others

End User Insights:

Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan companion diagnostics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan companion diagnostics market?
What is the breakup of the Japan companion diagnostics market on the basis of product & service?
What is the breakup of the Japan companion diagnostics market on the basis of technology?
What is the breakup of the Japan companion diagnostics market on the basis of indication?
What is the breakup of the Japan companion diagnostics market on the basis of end user?
What are the various stages in the value chain of the Japan companion diagnostics market?
What are the key driving factors and challenges in the Japan companion diagnostics?
What is the structure of the Japan companion diagnostics market and who are the key players?
What is the degree of competition in the Japan companion diagnostics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Companion Diagnostics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Companion Diagnostics Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Companion Diagnostics Market - Breakup by Product & Service

6.1 Assays, Kits and Reagents
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Software and Services
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)

7 Japan Companion Diagnostics Market - Breakup by Technology

7.1 Immunohistochemistry (IHC)
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Polymerase Chain Reaction (PCR)
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 In-situ Hybridization (ISH)
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Real-time PCR (RT-PCR)
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Gene Sequencing
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Others
- 7.6.1 Historical and Current Market Trends (2019-2024)
- 7.6.2 Market Forecast (2025-2033)

8 Japan Companion Diagnostics Market - Breakup by Indication

8.1 Cancer
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Segmentation
  - 8.1.3.1 Lung Cancer
  - 8.1.3.2 Breast Cancer
  - 8.1.3.3 Colorectal Cancer
  - 8.1.3.4 Gastric Cancer
  - 8.1.3.5 Melanoma
  - 8.1.3.6 Others
- 8.1.4 Market Forecast (2025-2033)
8.2 Neurological Diseases
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Infectious Diseases
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Cardiovascular Diseases
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)
8.5 Others
- 8.5.1 Historical and Current Market Trends (2019-2024)
- 8.5.2 Market Forecast (2025-2033)

9 Japan Companion Diagnostics Market - Breakup by End User

9.1 Pharmaceutical & Biopharmaceutical Companies
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
9.2 Reference Laboratories
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)
9.3 Contract Research Organizations
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)
9.4 Others
- 9.4.1 Historical and Current Market Trends (2019-2024)
- 9.4.2 Market Forecast (2025-2033)

10 Japan Companion Diagnostics Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Companion Diagnostics Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis